Bio-Techne (TECH) Stock Price

Bio-Techne Price

NASDAQ·CLOSED
72.12USD+0.35 (+0.49 %)
Market closed

Revenue has compounded at 9.9% per year over the past 19 years to 1.22 B USD. Earnings per share have declined at 0.0% per year over the last 19 years. Bio-Techne's net margin stands at 6.0%, down from 15.1% several years earlier. Bio-Techne currently offers a dividend yield of about 0.44%. The payout ratio is around 70% of earnings. The dividend has grown at 1.5% per year over the past 17 years. Analysts set a median price target of 71.40 USD, implying 1.0% below the current price. Of 23 analysts, 18 rate the stock a buy — an overall Buy consensus. The stock trades about 67% above its 52-week low.

Bio-Techne stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Bio-Techne over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Bio-Techne stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Bio-Techne's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Bio-Techne Stock Price History
DateBio-Techne Price
7/17/202672.12 USD
7/16/202671.77 USD
7/15/202671.48 USD
7/14/202671.23 USD
7/13/202671.35 USD
7/10/202671.30 USD
7/9/202671.15 USD
7/8/202670.52 USD
7/7/202670.61 USD
7/6/202670.79 USD
7/2/202670.83 USD
7/1/202671.00 USD
6/30/202670.65 USD
6/29/202670.96 USD
6/26/202671.00 USD
6/25/202670.70 USD
6/24/202658.88 USD
6/23/202656.26 USD
6/22/202655.97 USD
6/18/202657.10 USD
6/17/202656.53 USD
6/16/202655.68 USD
6/15/202655.99 USD
6/12/202654.39 USD
6/11/202652.85 USD
6/10/202653.26 USD
6/9/202654.41 USD
6/8/202652.65 USD
6/5/202652.18 USD
6/4/202652.79 USD
6/3/202649.76 USD
6/2/202649.71 USD
6/1/202651.34 USD
5/29/202651.51 USD
5/28/202650.39 USD
5/27/202647.58 USD
5/26/202647.95 USD
5/22/202647.39 USD
5/21/202646.71 USD
5/20/202645.58 USD
5/19/202645.47 USD
5/18/202644.43 USD
5/15/202643.30 USD
5/14/202644.74 USD
5/13/202644.89 USD
5/12/202647.42 USD
5/11/202647.42 USD
5/8/202648.36 USD
5/7/202650.91 USD
5/6/202647.41 USD
5/5/202656.68 USD
5/4/202654.74 USD
5/1/202655.02 USD
4/30/202655.32 USD
4/29/202651.95 USD
4/28/202653.51 USD
4/27/202655.11 USD
4/24/202654.19 USD
4/23/202652.20 USD
4/22/202658.58 USD
4/21/202659.67 USD
4/20/202660.58 USD
4/17/202659.23 USD
4/16/202657.36 USD
4/15/202658.49 USD
4/14/202658.66 USD
4/13/202657.53 USD
4/10/202655.54 USD
4/9/202655.57 USD
4/8/202655.21 USD
4/7/202653.83 USD
4/6/202653.80 USD
4/2/202653.13 USD
4/1/202653.48 USD
3/31/202652.26 USD
3/30/202652.04 USD
3/27/202650.95 USD
3/26/202652.70 USD
3/25/202652.69 USD
3/24/202652.43 USD
3/23/202652.00 USD
3/20/202651.86 USD
3/19/202651.59 USD
3/18/202651.59 USD
3/17/202651.06 USD
3/16/202648.81 USD
3/13/202650.85 USD
3/12/202651.51 USD
3/11/202653.62 USD
3/10/202652.82 USD
3/9/202654.87 USD
3/6/202653.89 USD
3/5/202655.89 USD
3/4/202657.85 USD
3/3/202656.99 USD
3/2/202657.82 USD
2/27/202659.00 USD
2/26/202657.92 USD
2/25/202657.87 USD
2/24/202657.60 USD
2/23/202654.76 USD
2/20/202657.52 USD
2/19/202658.25 USD
2/18/202659.33 USD
2/17/202658.50 USD
2/13/202659.93 USD
2/12/202659.54 USD
2/11/202663.45 USD
2/10/202664.80 USD
2/9/202665.48 USD
2/6/202666.78 USD
2/5/202665.86 USD
2/4/202668.67 USD
2/3/202664.63 USD
2/2/202665.25 USD
1/30/202664.09 USD
1/29/202663.98 USD
1/28/202665.53 USD
1/27/202668.23 USD
1/26/202667.63 USD
1/23/202668.16 USD
1/22/202669.65 USD
1/21/202671.38 USD
1/20/202669.57 USD
1/16/202668.67 USD
1/15/202669.96 USD
1/14/202668.40 USD
1/13/202666.36 USD
1/12/202666.56 USD
1/9/202665.70 USD
1/8/202664.58 USD
1/7/202665.05 USD
1/6/202665.28 USD
1/5/202663.03 USD
1/2/202659.65 USD
12/31/202558.81 USD
12/30/202559.12 USD
12/29/202559.24 USD
12/26/202559.22 USD
12/24/202559.19 USD
12/23/202559.25 USD
12/22/202558.96 USD
12/19/202558.27 USD
12/18/202557.10 USD
12/17/202556.99 USD
12/16/202557.44 USD
12/15/202558.69 USD
12/12/202558.51 USD
12/11/202560.26 USD
12/10/202560.83 USD
12/9/202558.82 USD
12/8/202560.32 USD
12/5/202561.68 USD
12/4/202563.54 USD
12/3/202563.82 USD
12/2/202562.95 USD
12/1/202563.76 USD
11/28/202564.51 USD
11/26/202564.63 USD
11/25/202565.85 USD
11/24/202563.49 USD
11/21/202561.53 USD
11/20/202558.73 USD
11/19/202557.81 USD
11/18/202558.15 USD
11/17/202558.61 USD
11/14/202559.38 USD
11/13/202560.75 USD
11/12/202561.40 USD
11/11/202559.18 USD
11/10/202557.46 USD
11/7/202557.41 USD
11/6/202558.18 USD
11/5/202559.94 USD
11/4/202560.51 USD
11/3/202561.26 USD
10/31/202562.57 USD
10/30/202560.96 USD
10/29/202562.02 USD
10/28/202563.94 USD
10/27/202564.25 USD
10/24/202566.21 USD
10/23/202566.06 USD
10/22/202563.79 USD
10/21/202563.46 USD
10/20/202563.31 USD
10/17/202562.16 USD
10/16/202561.60 USD
10/15/202559.58 USD
10/14/202559.27 USD
10/13/202559.65 USD
10/10/202558.53 USD
10/9/202559.90 USD
10/8/202560.56 USD
10/7/202559.19 USD
10/6/202561.92 USD
10/3/202563.07 USD
10/2/202562.10 USD
10/1/202559.92 USD
9/30/202555.63 USD
9/29/202552.23 USD
9/28/202552.23 USD
9/25/202551.85 USD
9/24/202550.48 USD
9/23/202553.21 USD
9/22/202553.04 USD
9/19/202553.28 USD
9/18/202552.99 USD
9/17/202551.52 USD
9/16/202551.78 USD
9/15/202551.62 USD
9/12/202551.01 USD
9/11/202553.21 USD
9/10/202550.96 USD
9/9/202554.20 USD
9/8/202554.11 USD
9/5/202554.36 USD
9/4/202552.92 USD
9/3/202553.34 USD
9/2/202553.42 USD
8/29/202554.64 USD
8/28/202554.33 USD
8/27/202556.22 USD
8/26/202556.79 USD
8/25/202556.71 USD
8/22/202557.02 USD
8/21/202554.00 USD
8/20/202554.33 USD
8/19/202554.87 USD
8/18/202553.29 USD
8/15/202553.83 USD
8/14/202553.74 USD
8/13/202554.71 USD
8/12/202552.83 USD
8/11/202550.15 USD
8/8/202550.20 USD
8/7/202550.15 USD
8/6/202549.87 USD
8/5/202554.64 USD
8/4/202554.88 USD
7/31/202554.89 USD
7/30/202554.73 USD
7/29/202557.71 USD
7/28/202557.87 USD
7/27/202558.55 USD
7/25/202559.30 USD
7/24/202558.95 USD
7/23/202555.31 USD
7/22/202553.12 USD
7/21/202550.27 USD
Access this data via the Eulerpool API
Get Free API Key

Bio-Techne Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
1.14 B USD
293.60 M USD
285.20 M USD
Jan 1, 2024
1.16 B USD
251.16 M USD
168.07 M USD
Jan 1, 2025
1.22 B USD
265.36 M USD
73.36 M USD
Jan 1, 2026 (e)
1.25 B USD
392.92 M USD
322.61 M USD
Jan 1, 2027 (e)
1.33 B USD
444.67 M USD
358.67 M USD
Jan 1, 2028 (e)
1.46 B USD
504.37 M USD
417.18 M USD
Jan 1, 2029 (e)
1.56 B USD
581.30 M USD
448.82 M USD
Jan 1, 2030 (e)
1.75 B USD
748.68 M USD
465.93 M USD

Bio-Techne Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 19, 2026, 9:00 AM
 
REVENUEB USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
DIV.USD
DIV. GROWTH%
SHARESM
20162017201820192020202120222023202420252026e2027e2028e2029e2030e2031e
0.500.560.640.710.740.931.111.141.161.221.251.331.461.561.752.19
10.4012.8314.2111.043.3626.1518.692.812.025.182.546.409.706.9212.0525.00
67.3366.4367.1966.2565.4567.8868.4267.6966.7066.5366.5366.5366.5366.5366.5366.53
0.340.370.430.470.480.630.760.770.770.810.830.880.971.041.161.45
153.00146.00161.00149.00150.00244.00298.00293.00251.00265.00392.00444.00504.00581.00748.00–
30.6625.9325.0420.8720.3326.2126.9725.7921.6621.7431.3633.3834.5437.2442.79–
104.0076.00126.0096.00229.00140.00271.00285.00168.0073.00322.00358.00417.00448.00465.00–
-2.80-26.9265.79-23.81138.54-38.8693.575.17-41.05-56.55341.1011.1816.487.433.79–
1.601.281.281.281.281.601.280.400.320.320.320.320.32–––
25.00-20.00–––25.00-20.00-68.75-20.00–––––––
149.30150.00152.20155.60157.60161.90164.10161.90160.77159.72159.72159.72159.72159.72159.72159.72
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Bio-Techne generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Bio-Techne retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Bio-Techne's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Bio-Techne has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Bio-Techne's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Bio-Techne stock margins

The Bio-Techne margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Bio-Techne. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Bio-Techne.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
67.98 %
26.31 %
15.07 %
Jan 1, 2022
68.42 %
26.97 %
24.59 %
Jan 1, 2023
67.72 %
25.83 %
25.09 %
Jan 1, 2024
66.70 %
21.67 %
14.50 %
Jan 1, 2025
66.50 %
21.76 %
6.02 %
Jan 1, 2026 (e)
66.50 %
31.43 %
25.81 %
Jan 1, 2027 (e)
66.50 %
33.43 %
26.97 %
Jan 1, 2028 (e)
66.50 %
34.57 %
28.59 %

Bio-Techne Stock Revenue, EBIT, Earnings per Share

The Bio-Techne earnings per share therefore indicates how much revenue Bio-Techne has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
5.75 USD
1.51 USD
0.87 USD
Jan 1, 2022
6.74 USD
1.82 USD
1.66 USD
Jan 1, 2023
7.02 USD
1.81 USD
1.76 USD
Jan 1, 2024
7.21 USD
1.56 USD
1.05 USD
Jan 1, 2025
7.64 USD
1.66 USD
0.46 USD
Jan 1, 2026 (e)
7.83 USD
2.46 USD
2.02 USD
Jan 1, 2027 (e)
8.33 USD
2.78 USD
2.25 USD
Jan 1, 2028 (e)
9.13 USD
3.16 USD
2.61 USD

Bio-Techne business model & stock analysis

Bio-Techne Corp is a global company specializing in the research and development of innovative products and solutions in the field of biosciences. The company was founded in 1976 in Minneapolis and was formerly known as Techne Corporation. Since then, it has grown into an internationally renowned company through its numerous acquisitions and mergers. The company is headquartered in Minneapolis, Minnesota, USA. The business philosophy of Bio-Techne Corp is to help bioscientific researchers and clinicians around the world perform their work more effectively, efficiently, and quickly. The company works closely with its customers to provide them with suitable products and services, thereby developing innovative solutions to the challenges in bioscience. Bio-Techne Corp has various business segments, including protein platforms, diagnostics, genetic analysis, clinical controls, cell culture products, and research reagents. Each business segment offers a variety of products and services to support researchers and clinicians in their work. A key business segment of Bio-Techne Corp is the protein platform, which offers a comprehensive range of proteins, antibodies, and corresponding detection reagents. The company is known for its high-quality proteins and antibodies, which contribute to improving the research of diseases such as cancer, diabetes, and neurological and immunological disorders. Another important business segment of Bio-Techne Corp is diagnostics. Here, the company offers a wide range of clinical diagnostic products, such as tests for analyzing urea, creatinine, and bone density. The company's products help clinicians make precise diagnoses and treat patients more effectively. The genetic analysis segment offers DNA sequencing, gene expression, and genome-wide analysis products and services. These tools enable researchers to better understand the functioning of the human body by exploring the underlying genetic changes. The clinical controls segment offers product and service offerings that improve the reliability and accuracy of diagnostic systems. The company works closely with medical facilities to provide diagnostic solutions that deliver fast and accurate results. The cell culture products segment offers a complete range of solutions for cell cultivation and growth. The offering ranges from basic nutrient media and additives to culture vessels and accessories. The company's products enable researchers to culture cells in a controlled environment and under precise conditions. The last segment of Bio-Techne Corp includes research reagents. Here, the company offers a wide range of reagents used for protein, antibody, and cell function analysis and research. The products meet the needs of researchers in modern bioscience. In summary, Bio-Techne Corp is a company specialized in developing innovative solutions in bioscience, advancing science and medicine. With its products and services offered in various sectors, the company successfully helps researchers and clinicians perform their work faster, more effectively, and cost-efficiently.

Bio-Techne SWOT Analysis

Strengths

[ { "heading": "1.", "text": "Strong" }, { "heading": "2.", "text": "Robust" }, { "heading": "3.", "text": "Established" }, { "heading": "4.", "text": "Strong" } ]

Weaknesses

[ { "heading": "1.", "text": "Reliance" }, { "heading": "2.", "text": "Limited" }, { "heading": "3.", "text": "High" }, { "heading": "4.", "text": "Potential" } ]

Opportunities

[ { "heading": "1.", "text": "Growing" }, { "heading": "2.", "text": "Expansion" }, { "heading": "3.", "text": "Acquisitions" }, { "heading": "4.", "text": "Increasing" } ]

Threats

[ { "heading": "1.", "text": "Economic" }, { "heading": "2.", "text": "Intellectual" }, { "heading": "3.", "text": "Rapid" }, { "heading": "4.", "text": "Regulatory" } ]

Bio-Techne Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Bio-Techne historical P/E ratio, EBIT multiple, and P/S ratio

Bio-Techne annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Bio-Techne shares outstanding

The number of shares of Bio-Techne was 159.72 M in 2025. This indicates how many shares Bio-Techne is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
161.90 M Stocks
Jan 1, 2022
164.10 M Stocks
Jan 1, 2023
161.90 M Stocks
Jan 1, 2024
160.77 M Stocks
Jan 1, 2025
159.72 M Stocks
Jan 1, 2026 (e)
159.72 M Stocks
Jan 1, 2027 (e)
159.72 M Stocks
Jan 1, 2028 (e)
159.72 M Stocks

Bio-Techne stock splits

In Bio-Techne's history, there have been no stock splits.

Bio-Techne Dividend History

19 years of dividend payments

YearAnnual DividendYoY ChangePayments
20260.16USDYTD—2×
Feb 13, 20260.08USD 0.0%1/2
May 18, 20260.08USD 0.0%2/2
20250.32USD 0.0%4×
Feb 14, 20250.08USD 0.0%1/4
May 19, 20250.08USD 0.0%2/4
Aug 18, 20250.08USD 0.0%3/4
Nov 17, 20250.08USD 0.0%4/4
20240.32USD↓ 20.0%4×
20230.40USD↓ 68.8%5×
20221.28USD↓ 19.9%6×
20211.60USD↑ 25.1%6×
20201.28USD 0.0%4×
20191.28USD 0.0%4×
20181.28USD 0.0%4×
20171.28USD↓ 20.0%4×

Bio-Techne dividend history and estimates

In 2025, Bio-Techne paid a dividend amounting to 0.32 USD. Dividend means that Bio-Techne distributes a portion of its profits to its owners.

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2021
1.60 USD
0.00 USD
Jan 1, 2022
1.28 USD
0.00 USD
Jan 1, 2023
0.40 USD
0.00 USD
Jan 1, 2024
0.32 USD
0.00 USD
Jan 1, 2025
0.32 USD
0.00 USD
Jan 1, 2026
0.32 USD
0.00 USD
Jan 1, 2027 (e)
0.00 USD
0.32 USD
Jan 1, 2028 (e)
0.00 USD
0.32 USD

Bio-Techne dividend payout ratio

In 2025, Bio-Techne had a payout ratio of 69.67%. The payout ratio indicates the percentage of the company's profits that Bio-Techne distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2021
46.16 %
Jan 1, 2022
19.47 %
Jan 1, 2023
22.73 %
Jan 1, 2024
30.61 %
Jan 1, 2025
69.67 %
Jan 1, 2026 (e)
15.84 %
Jan 1, 2027 (e)
14.25 %
Jan 1, 2028 (e)
12.25 %

Current Bio-Techne forecasts and price targets in July 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy78.26 % (18)
Hold21.74 % (5)
Sell0.00 % (0)
12M Price Target
71.40
Last Price
72.12
Currency
USD
12M Return Potential
-1.00 %
LTM Return
0 %

Bio-Techne Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
5/6/20260.55USD323.43 MUSD2026 Q3
2/4/20260.44USD295.99 MUSD2026 Q2
2/3/20260.44USD295.99 MUSD2026 Q2
5/1/20240.50USD311.61 MUSD2024 Q3
1/31/20240.42USD283.69 MUSD2024 Q2
8/2/20232.42USD330.35 MUSD2023 Q4
5/2/20232.31USD320.99 MUSD2023 Q3
1/30/20231.99USD296.47 MUSD2023 Q2
11/1/20221.87USD285.96 MUSD2023 Q1
8/4/20222.12USD291.43 MUSD2022 Q4
...

EESG©

Eulerpool ESG Scorecard© for the Bio-Techne stock

72/100
58
Environment
99
Social
59
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees49
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees61
White Management Share74
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Bio-Techne shareholder structure

% Name
11.51894%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
5.50550%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
5.39471%
T. Rowe Price Associates, Inc.
T. Rowe Price Associates, Inc.
3.66810%
State Street Investment Management (US)
State Street Investment Management (US)
2.68863%
Atlanta Capital Management Company, L.L.C.
Atlanta Capital Management Company, L.L.C.
2.54357%
Geode Capital Management, L.L.C.
Geode Capital Management, L.L.C.
...

Bio-Techne Executives and Management Board

KK

Mr. Kim Kelderman

(58)

President, Chief Executive Officer, Director · since 2018

Compensation8.15 M USD
JH

Mr. James Hippel

(54)

Chief Financial Officer, Executive Vice President - Finance

Compensation7.03 M USD
WG

Mr. William Geist

(56)

President - Protein Sciences

Compensation3.14 M USD
MM

Dr. Matthew Mcmanus

(56)

President - Diagnostics and Spatial Biology

Compensation2.85 M USD
SB

Mr. Shane Bohnen

(50)

Senior Vice President, General Counsel, Corporate Secretary

Compensation1.98 M USD

Bio-Techne Supply Chain

Bio-Techne Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
15 companies
#Name1M3M6M1Y2YTrend
1
Danaher
Supplier
0.84
0.96
0.89
0.83
0.90
2
Transcat
Supplier
0.42
0.79
0.55
-0.08
0.79
3
Thermo Fisher Scientific
0.81
0.80
0.83
0.38
0.77
4
Celcuity
0.41
0.75
0.66
0.66
0.68
5
Renalytix
Supplier
0.43
0.64
0.55
0.66
0.41
#Name1M3M6M1Y2YTrend
1
Quanterix
Supplier
0.88
0.89
0.85
0.75
—
2
908 Devices
Supplier
0.80
0.79
0.86
0.79
—
3
C4 Therapeutics
Supplier
0.78
0.76
0.74
0.88
—
4
Akoya Biosciences
Supplier
0.50
0.74
0.75
0.57
—
5
Janel
Supplier
-0.03
-0.68
—
—
—

Frequently asked questions about Bio-Techne

Bio-Techne Corp's business model revolves around providing innovative life science tools and solutions to researchers worldwide. The company focuses on developing and manufacturing high-quality reagents, assays, and instruments used in biomedical research, clinical diagnostics, and pharmaceutical development. With a diverse portfolio, Bio-Techne offers products for gene expression analysis, protein analysis, cell imaging, and stem cell research. Their advanced technologies and expertise enable scientists to accelerate discoveries and enhance their understanding of diseases, ultimately aiding in the development of new therapies. Bio-Techne Corp strives to be at the forefront of scientific advancements by continually investing in research and development initiatives.

All fundamentals and in-depth analysis of Bio-Techne

Our stock analysis for Bio-Techne stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Bio-Techne. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Bio-Techne Stock
Bio-Techne Revenue→
Bio-Techne Stock
Bio-Techne Net Income→
Bio-Techne Stock
Bio-Techne P/E→
Bio-Techne Stock
Bio-Techne P/S→
Bio-Techne Stock
Bio-Techne EBIT→
Bio-Techne Stock
Bio-Techne Dividend→
Bio-Techne Stock
Bio-Techne Directors Dealings→
Bio-Techne Stock
Bio-Techne Stocks→
Bio-Techne Stock
Bio-Techne Market capitalization→
Bio-Techne Stock
Bio-Techne Debt→
Bio-Techne Stock
Bio-Techne Liabilities→
Bio-Techne Stock
Bio-Techne Equity→
Bio-Techne Stock
Bio-Techne AAQS→
Bio-Techne Stock
Bio-Techne Employees→
Bio-Techne Stock
Bio-Techne ROE→
Bio-Techne Stock
Bio-Techne ROA→
Bio-Techne Stock
Bio-Techne ROCE→
Bio-Techne Stock
Bio-Techne News→
Bio-Techne Stock
Bio-Techne Analyst Price Targets→

Health Stocks

Bio-Thera SolutionsBio-FD&C CoBio-Works TechnologiesBio ViewbioAffinity TechnologiesBio Solution CoBIOAGE LabsBio Rad LaboratoriesBioArcticBio Preventive MedicineBioatlaBio Plus CoAll Stocks A–Z →